ライフサイエンスコーパス: deoxyuridine

1 ) lung macrophages incorporated 5-ethynyl-2'-deoxyuridine.

2 for 2'-deoxyuridine and 5-(hydroxymethyl)-2'-deoxyuridine.

3 the folate-deficient diet supplemented with deoxyuridine.

4 ely 300 times lower than that of 5-formyl-2'-deoxyuridine (0.011 lesions per 10(6) nucleosides per Gy

5 o degraded intracellularly to 5-radioiodo-2'-deoxyuridine 1 and its monophosphate 20, respectively, w

6 rboxy-2'-deoxycytidine, 5-(hydroxymethyl)-2'-deoxyuridine, 2'-deoxyuridine, and 8-oxo-2'-deoxyguanosi

7 chemistries associated with inflammation: 2'-deoxyuridine, 2'-deoxyxanthosine and 2'-deoxyinosine fro

8 of 3-N-benzoyl-3',5'-di-O-benzoyl-5-iodo-2'-deoxyuridine (2a) and 3-N-benzoyl-3',5'-di-O-benzoyl-5-i

9 wing new nucleosides: 5-(dimethoxymethyl)-2'-deoxyuridine (2b), 5-(diethoxymethyl)-2'-deoxyuridine (3

10 -2'-deoxyuridine (2b), 5-(diethoxymethyl)-2'-deoxyuridine (3b), 5-formyl-2'-deoxyuridine ethylene ace

11 F-2dUrd), and hexadecyloxypropyl 5-fluoro-2'-deoxyuridine 5'-monophosphate (HDP-P-5-F-2dUrd) were syn

12 betamethason phosphate, FdUMP = 5'-fluoro-2'-deoxyuridine 5'-monophosphate).

13 cil-based acyclic compounds as inhibitors of deoxyuridine 5'-triphosphate nucleotidohydrolase (dUTPas

14 rminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphospate nick end labeling).

15 vFLIP, can metabolize the prodrug 5-fluoro-5-deoxyuridine (5-dFUrd) to 5-fluouridine (5-FU), a potent

16 by measuring nucleotide analog 5-ethynyl-2'-deoxyuridine (5-EdU) incorporation into the DNA and isle

17 abinofuranosylguanine (AraG) and 5-fluoro-2'-deoxyuridine (5-F-2dUrd).

18 cally deaminated to yield 5-hydroxymethyl-2'-deoxyuridine (5-HmdU).

19 ted for the terminal transferase-mediated 2'-deoxyuridine, 5'-triphosphate nick end-labeling assay an

20 and terminal deoxynucleotidyl transferase 2-deoxyuridine, 5-triphosphate nick end-labeling analyses

21 containing the VZ were exposed to 5-bromo-2'-deoxyuridine-5'-monophosphate (BrdU) in vitro.

22 5) catalyzes the reductive methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) by N(5),N(10)-methy

23 its complex with Escherichia coli TS and 2'-deoxyuridine-5'-monophosphate, and a model for a similar

24 e the methylation of the uracil moiety of 2'-deoxyuridine-5'-monophosphate.

25 ve site residue of the enzyme to activate 2'-deoxyuridine-5'-monophosphate.

26 5% of thymidine (T) with 5'-hydroxymethyl-2'-deoxyuridine (5hmU) in the Escherichia coli genome.

27 -(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine 8 and 5-radioiodo-3'-O-(17beta-succinyl-5al

28 starting from acetyl-protected 5-alkynyl-2'-deoxyuridines (85-86%).

29 EdU (ethynyl deoxyuridine, a thymidine analog) and annexin-propidium

30 Using 5-bromo-2-deoxyuridine administration at P2, P11, P22, or P120-P12

31 ficiently and had a 5-fold reduced thymidine/deoxyuridine affinity.

32 ethanesulfonate (MMS) and 5-hydroxymethyl-2'-deoxyuridine, agents that introduce base excision repair

33 5-(Thien-2-yl)-2'-deoxyuridine, an isomorphic fluorescent nucleoside analo

34 This deoxyuridine analog also displays a mega-Stokes shift, w

35 oligodeoxynucleotides (ODNs) of an emissive deoxyuridine analog electronically conjugated on its C5-

36 When incorporated in ODNs, this fluorescent deoxyuridine analog exhibits remarkable photostability a

37 ther nucleotides, including 5-substituted 2'-deoxyuridine analogs, once they have been flipped from t

38 No such differences was found for 2'-deoxyuridine and 5-(hydroxymethyl)-2'-deoxyuridine.

39 5-ethynyl-2'-deoxyuridine and 5-bromo-2'-deoxyuridine incorporation a

40 Once again, only 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine are pr

41 re because only compounds 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine were f

42 hat two of our compounds, 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine, shoul

43 Sequential administration of 5-chloro-2-deoxyuridine and 5-iodo-2-deoxyuridine indicated that al

44 h BSM cell proliferation by using 5-bromo-2'-deoxyuridine and cell counting and in the expression of

45 Injection of 5-bromo-2'-deoxyuridine and immunocytochemistry showed that the pri

46 saturated pyrimidine lesions, 5,6-dihydro-2'-deoxyuridine and pyrimidine (6-4) pyrimidone photoproduc

47 bovine uridine phosphorylase treated with 2'-deoxyuridine and sulfate show intact nucleoside.

48 e natural pyrimidine nucleosides uridine, 2'-deoxyuridine and thymidine inhibited mycoplasma-associat

49 In contrast, in undamaged 2'-deoxyuridine and thymidine, reactions at elevated temper

50 with similar specificity for uridine and 2'-deoxyuridine and undetectable activity toward thymidine

51 ansporter had low affinity for uridine and 2'deoxyuridine and was the sole pyrimidine transporter exp

52 ardiomyocytes demonstrated EdU (5-ethynyl-2'-deoxyuridine) and phosphorylated histone H3 positivity i

53 idine, 5-(hydroxymethyl)-2'-deoxyuridine, 2'-deoxyuridine, and 8-oxo-2'-deoxyguanosine.

54 acillus subtilis P RNA with 4-thiouridine, 4-deoxyuridine, and abasic modifications and G378/379 with

55 e knockout mice with exogenous thymidine and deoxyuridine, and assessed clinical, neuroradiological,

56 e assessed by labeling cells with 5-bromo-2'-deoxyuridine, and fecal microbial community composition

57 yribose was synthesized using carbocyclic 2'-deoxyuridine as starting material.

58 Cs within the myocardium, whereas 5-bromo-2'-deoxyuridine assays revealed de novo in vivo cardiomyocy

59 -induced deaminase converts deoxycytidine to deoxyuridine at the Ig loci.

60 antibodies and the other using a 5-ethynyl-2-deoxyuridine-based chemical reaction, only after the eme

61 Using 5-bromo-2-deoxyuridine birthdating to identify newborn cells, we f

62 FP to tag the newborn rods and by 5-bromo-2'-deoxyuridine birthdating, we demonstrate that early-born

63 itions and either 5-(N-benzylcarboxamide)-2'-deoxyuridine (Bn-dU) or 5-[N-(1-naphthylmethyl)carboxami

64 Treatment of cultured cells with 5-bromo-2'-deoxyuridine ((Br)dU) is known to result in the substitu

65 metazoans in response to analogs 5-bromo-2'-deoxyuridine (BrdU) and 5-ethynyl-2'-deoxyuridine (EdU).

66 Systemic injections of 5-bromo-2'-deoxyuridine (BrdU) and intraventricular injections of r

67 We used 5'-bromo-2'-deoxyuridine (BrdU) and retroviral methodologies to birt

68 labeled with the nucleotide analog 5-bromo-2-deoxyuridine (BrdU) and sorted into S-phase fractions on

69 beled with the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU) and their identity was determined im

70 transected and injected with 5-bromo-2&prime-deoxyuridine (BrdU) at 0-3 weeks posttransection.

71 gions by injecting quail eggs with 5-bromo-2-deoxyuridine (BrdU) at various stages between embryonic

72 beled by subretinal injection of 5'-bromo-2'-deoxyuridine (BrdU) followed by immunohistochemistry.

73 5-Bromo-2'-deoxyuridine (BrdU) has been investigated as a radiosens

74 peritoneally (IP) with 50 mg/kg of 5-bromo-2-deoxyuridine (BrdU) immediately after anesthesia.

75 l proliferation was determined by 5-bromo-2'-deoxyuridine (BrdU) immunohistochemistry and by cell cou

76 was measured by administration of 5-bromo-2'-deoxyuridine (BrdU) in the drinking water.

77 es in [methyl-(3)H] thymidine and 5-bromo-2'-deoxyuridine (BrdU) incorporation and in the number of c

78 Hepatic cellular 5-bromo-2'-deoxyuridine (BrdU) incorporation increased from 0.2% af

79 Using 5-Bromo-2'-deoxyuridine (BrdU) incorporation to generate genome-wid

80 hrough flow cytometric analysis of 5-bromo-2'deoxyuridine (BrdU) incorporation.

81 le Macaca fascicularis) were given 5-bromo-2-deoxyuridine (BrdU) injections 2-3 weeks after the rhizo

82 The replacement of thymidine with 5-bromo-2'-deoxyuridine (BrdU) is well-known to sensitize cells to

83 Monocyte progenitors were 5-bromo-2'-deoxyuridine (BrdU) labeled in bone marrow, and CNS macr

84 Mathematical modeling of 5-bromo-2' deoxyuridine (BrdU) labeling dynamics demonstrated a sig

85 We examined single-pulse S-phase bromo-deoxyuridine (BrdU) labeling in the dentate granule laye

86 Rather, 5-bromo-2'-deoxyuridine (BrdU) labeling studies suggest that many o

87 determined using ImageJ software, and bromo-deoxyuridine (BrdU) labeling was used to visualize proli

88 incorporation of new nuclei using 5-bromo-2-deoxyuridine (BrdU) labelling by isolating individual my

89 the bone marrow to the DRGs using 5-bromo-2-deoxyuridine (BrdU) pulse, and serially measured IENFD.

90 Using these models, along with a 5-bromo-2'-deoxyuridine (BrdU) pulse-label strategy, we compared me

91 lyzed the cell cycle change using 5-bromo-2'-deoxyuridine (BrdU) pulse-labeling and DAPI (4',6-diamid

92 ith the "gold standard" method of 5-bromo-2'-deoxyuridine (BrdU) staining using two behavioral paradi

93 We used 5-bromo-2'-deoxyuridine (BrdU) to identify and localize proliferati

94 one intraperitoneal injection of 5-bromo-2'-deoxyuridine (BrdU) to label progenitors in the hippocam

95 The S-phase mitotic marker 5'-bromo-2'-deoxyuridine (BrdU) was administered at the conclusion o

96 ranule cells, single injections of 5-bromo-2-deoxyuridine (BrdU) with different survival times were c

97 By using 5-bromo-2'-deoxyuridine (BrdU), a label-retaining cell population w

98 Nucleoside 5-bromo-2'-deoxyuridine (BrdU), after being incorporated into cellu

99 ocytes are typically labeled with 5-bromo-2'-deoxyuridine (BrdU), deuterium, or the fluorescent dye c

100 osed to retain DNA labels, such as 5-bromo-2-deoxyuridine (BrdU), either because they segregate chrom

101 opulations are pulse-labeled with 5-bromo-2'-deoxyuridine (BrdU), fractionated according to cell-cycl

102 For example, the percentage of 5-bromo-2'-deoxyuridine (BrdU)-labeled cells in epithelial layer wa

103 OP3-4 enhanced the BMP-2-induced 5-bromo-2'-deoxyuridine (BrdU)-positive cell numbers at the injecte

104 animals also received intravenous 5-bromo-2-deoxyuridine (BrdU).

105 rain of an anuran amphibian using 5-bromo-2'-deoxyuridine (BrdU).

106 ay 5 with an intravenous pulse of 5-bromo-2'-deoxyuridine (BrdU).

107 of the marker of DNA replication 5-bromo-2'-deoxyuridine (BrdU).

108 oliferation, the exogenous marker 5-bromo-2'-deoxyuridine (BrdU, 200mg/kg, ip) was administered 2h in

109 5-Bromo-2-deoxyuridine (BrdU, 50 mg/kg) was intraperitoneally deli

110 g treatment, the thymidine analog 5-bromo-2'-deoxyuridine (BrdU; 200 mg/kg, i.p.) was administered tw

111 both the neuronal marker NeuN and 5-bromo-2'-deoxyuridine (BrdU; a marker for proliferating cells) in

112 rs for tumor proliferation (Ki67, 5-bromo-2'-deoxyuridine [BrdU]) and cell death (caspase-3, terminal

113 or control treatments, followed by 5-bromo-2-deoxyuridine (BrdUrd) in drinking water for four weeks b

114 5-Bromo-2-deoxyuridine (BrdUrd) was administered to tumor-bearing

115 The removal of the interfering deoxyuridine by UNG, however, activated the DNAzyme.

116 We confirmed using 5-ethynyl-2'-deoxyuridine click chemistry that the Oc-Cre lineage inc

117 lies on the four building blocks 5-chloro-2'-deoxyuridine (ClU), A, C and G instead of the standard T

118 1'-Cyano-2'-deoxyuridine (CNdU) and related molecules may prove usef

119 1'-Cyano-2'-deoxyuridine (CNdU) is a nanomolar competitive inhibitor

120 esulting from APOBEC activity are avoided by deoxyuridine conversion to abasic sites ahead of nascent

121 table lipid prodrugs of AraG and 5-fluoro-2'-deoxyuridine could be long-lasting, slow-release, antipr

122 (HDP-P-AraG), hexadecyloxypropyl 5-fluoro-2'-deoxyuridine cyclic 3',5'-monophosphate (HDP-cP-5-F-2dUr

123 f the oxygen in the 5,6-dihydro-6-hydroxy-2'-deoxyuridine derived from 2.

124 es in two pyrimidine lesions: 5,6-dihydro-2'-deoxyuridine (dHdU) and 5,6-dihydrothymidine (dHT), form

125 spore photoproduct" (SP), and 5,6-dihydro-2'-deoxyuridine (dHdU), formed via ionizing radiation damag

126 trypanocidal activity; 5F-orotic acid, 5F-2'deoxyuridine displayed activity in the low micromolar ra

127 nucleotide analogue 5-dimethylaminopropargyl deoxyuridine (DMAPdU) in place of thymidine and examined

128 gate the incorporation of deoxythymidine --> deoxyuridine (dT --> dU) substitutions in the duplex and

129 To generate target molecules, a single deoxyuridine (dU) residue is placed 6-10 nt away from th

130 th propidium iodide (PI) and/or 5-ethynyl-2'-deoxyuridine (EdU) (S-phase label) and imaged by confoca

131 , based on the incorporation of 5-ethynyl-2'-deoxyuridine (EdU) and its subsequent detection by a flu

132 incorporation and detection of 5-ethynyl-2'-deoxyuridine (EdU) in fission yeast, a thymidine analogu

133 ing "click chemistry" to detect 5-ethynyl-2'-deoxyuridine (EdU) incorporation into replicating viral

134 ex, macrophage DNA content, and 5-ethynyl-2'-deoxyuridine (EdU) incorporation such that it was possib

135 and migration was evaluated by 5-ethynyl-2'-deoxyuridine (EdU) incorporation, cell count, and Boyden

136 ew perspective, we incorporated 5-ethynyl-2'-deoxyuridine (EdU) into nascent DNA in cells infected wi

137 abeling of the thymidine analog 5-ethynyl-2'-deoxyuridine (EdU) into nascent viral DNA during cellula

138 Based on cumulative 5-ethynyl-2'-deoxyuridine (EdU) labeling as well as Ki67 and prolifer

139 We combined 5-ethynynl-2'-deoxyuridine (EdU) labeling with antibody markers that i

140 (aPC) and used prelabeling with 5-ethynyl-2'-deoxyuridine (EdU) to assess cell proliferation.

141 eling of proliferating cells by 5-ethynyl-2'-deoxyuridine (EdU) to profile individual dividing cells.

142 d based on the incorporation of 5-ethynyl-2'-deoxyuridine (EdU), a thymidine analogue, into cellular

143 n-1 (Magp1) in conjunction with 5-ethynyl-2'-deoxyuridine (EdU), an S-phase marker.

144 elutriation, labeled cells with 5-ethynyl-2'-deoxyuridine (EdU), and then treated each population wit

145 5-ethynyl-2'deoxyuridine (EdU)-a thymidine analog-containing minipum

146 Following adoptive transfer of 5-ethynyl-2'-deoxyuridine (EdU)-labeled hemocytes, labeled cells popu

147 microscopic analyses involving 5-ethynyl-2'-deoxyuridine (EdU)-labeled pseudogenomes and antibodies

148 stomorphometry, using Ki-67 and 5-ethynyl-2'-deoxyuridine (EdU).

149 romo-2'-deoxyuridine (BrdU) and 5-ethynyl-2'-deoxyuridine (EdU).

150 DNA with the nucleoside analog 5-ethynyl-2'-deoxyuridine (EdU).

151 oxymethyl)-2'-deoxyuridine (3b), 5-formyl-2'-deoxyuridine ethylene acetal (4b), and 5-formyl-2'-deoxy

152 NAs were designed that contained 5-fluoro-2'-deoxyuridine (FdU) moieties at various locations within

153 The antitumor drug 5-fluoro-2'-deoxyuridine (FdUrd) also sensitizes tumor cells to ioni

154 Nucleoside 5-formyl-2'-deoxyuridine (FodU) is a major thymidine lesion generate

155 Catalytic reduction (5% Rh/alumina) of 2'-deoxyuridine, followed by reduction with sodium borohydr

156 Animals received 5-bromo-2-deoxyuridine for 6 days.

157 Two novel series of 5-fluoroalkyl-2'-deoxyuridines (FPrDU, FBuDU, FPeDU) and 2'-fluoro-2'-deo

158 ic drugs: 5-fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FUDR), and camptothecin (CPT).

159 t a novel mechanism for error-free bypass of deoxyuridines generated within ssDNA and suggest that th

160 order of catalytic efficiencies: thymidine > deoxyuridine >> deoxyinosine > deoxyguanosine.

161 or deamination of hmdC to 5-hydroxymethyl-2'-deoxyuridine (hmdU).

162 , slowly cycling cells by tracking 5-iodo-2'-deoxyuridine (IdU) label-retaining cells (LRCs) in norma

163 ts into the pathogenic role of thymidine and deoxyuridine imbalance in mitochondrial neurogastrointes

164 (Kd = 0.20 nm) modified at the 5-position of deoxyuridine in a complex with IL-6.

165 ysis of the N-glycosidic bond, converting 2'-deoxyuridine in DNA to an abasic site, was continuously

166 etoglutarate/O(2)-dependent hydroxylation of deoxyuridine in fungal extracts have been reported previ

167 of the pyrimidine nucleosides thymidine and deoxyuridine in plasma and tissues, and somatic multiple

168 ase (AID), which deaminates deoxycytidine to deoxyuridine in single-stranded DNA (ssDNA).

169 nase that converts deoxycytidine residues to deoxyuridine in single-stranded DNA (ssDNA).

170 evere TP deficiency, increased thymidine and deoxyuridine in tissues and elevated mitochondrial deoxy

171 activity deficiency, elevated thymidine and deoxyuridine in tissues, mitochondrial DNA depletion, re

172 Incorporation of 5-bromo-2-deoxyuridine in vivo increased in neurogenic areas in ad

173 cell DNA synthesis by detection of 5-bromo-2-deoxyuridine incorporated into the nuclei of crypt cells

174 transcription factor Fli1 were generated by deoxyuridine incorporation and endonuclease V cleavage.

175 m progenitor cells were detected using bromo-deoxyuridine incorporation and Ki67 immunostaining.

176 crease but not complete elimination of bromo-deoxyuridine incorporation and mitoses at 24 hours after

177 ected for in vivo experiments based on bromo-deoxyuridine incorporation and terminal deoxynucleotidyl

178 5-ethynyl-2'-deoxyuridine and 5-bromo-2'-deoxyuridine incorporation assays were used to study pat

179 strated increased growth rates and 5-bromo-2-deoxyuridine incorporation for HGF fibroblasts.

180 sing fluorescence microscopy of 5-ethynyl-2'-deoxyuridine incorporation in fixed cells.

181 al protein S6 phosphorylation and 5-bromo-2'-deoxyuridine incorporation in wild-type but not CB(2) re

182 s of cell-cycle progression and 5-ethynyl-2'-deoxyuridine incorporation through flow cytometry reveal

183 5-Bromo-2'-deoxyuridine incorporation was 25% in LPG but only 5% in

184 Proliferation was measured by 5-bromo-2'-deoxyuridine incorporation, [(3)H]thymidine incorporatio

185 proliferation was evaluated with 5-bromo-2'-deoxyuridine incorporation, and cell size assessed by fl

186 estigated by morphometric analysis, bromo-2'-deoxyuridine incorporation, and immunostaining.

187 trombopag neither led to increased 5-bromo-2-deoxyuridine incorporation, decreased apoptosis, an incr

188 -associated beta-galactosidase and 5-bromo-2-deoxyuridine incorporation, in normal but not cancerous

189 tor) treatments, as determined by 5-bromo-2'-deoxyuridine incorporation, Ki-67 staining and clonogeni

190 5-Bromo-2'-deoxyuridine incorporation, proliferating cell nuclear a

191 heir proliferation as measured by 5-bromo-2'-deoxyuridine incorporation.

192 ll cycle transition and decreases 5-bromo-2'-deoxyuridine incorporation.

193 erative response was confirmed by 5-bromo-2'-deoxyuridine incorporation.

194 Proliferation was quantified by 5-bromo-2'-deoxyuridine incorporation.

195 e-treated cells as determined by 5'-bromo-2'-deoxyuridine incorporation.

196 f the cell cycle, decreased BrdU (5-bromo-2'-deoxyuridine) incorporation, and led to increased expres

197 tion of 5-chloro-2-deoxyuridine and 5-iodo-2-deoxyuridine indicated that all HSCs segregate their chr

198 ectrophysiological measures; BrdU (5-bromo-2-deoxyuridine) injections were used to quantify cell surv

199 modified nucleotides such as 5-N-carboxamide-deoxyuridines into random nucleic acid libraries improve

200 ith 5-azacytidine (AzaC) and with 5'-iodo-2'-deoxyuridine (IUdR); none was detected with sodium butyr

201 use a massive dispersion of BrdU (5-bromo-2'-deoxyuridine)-labeled neuroblasts into surrounding brain

202 1/2-, nuclear beta-catenin-, and 5-bromo-2'-deoxyuridine-labeled cells and altered keratin (K) 14 (K

203 n increase in the percentage of 5-ethynyl-2'-deoxyuridine-labeled myocytes.

204 y the phenotype of newborn cells (5-bromo-2'-deoxyuridine-labeled) with various cellular markers; dou

205 5-Bromo-2'-deoxyuridine labeling and increases of graft weight were

206 High 5-bromo-4-deoxyuridine labeling in Delta5PTEN papillomas showed th

207 5-Bromo-2'-deoxyuridine labeling reveals that cyst-lining epithelia

208 was successfully detected and quantified by deoxyuridine-modified DNAzymes that underwent UNG-depend

209 logue, 5-(1-phenyl-1H-1,2,3-triazol-4-yl)-2'-deoxyuridine monomer W in oligonucleotides, has demonstr

210 published 5-(1-phenyl-1,2,3-triazol-4-yl)-2'-deoxyuridine monomer W.

211 at is the 5-(4-phenyl-1,2,3-triazol-1-yl)-2'-deoxyuridine monomer Y, was found to destabilize the DNA

212 Finally, the 5-phenyl-2'-deoxyuridine monomer Z was incorporated for comparison,

213 ns that prevents the stable incorporation of deoxyuridine monophosphate into DNA in the form of U/A b

214 ected DNA fragments containing a 5'-terminal deoxyuridine monophosphate.

215 nd decreased the number of BrdU+ (5-bromo-2'-deoxyuridine+) myocytes detected at the infarct border z

216 U) or 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine (Nap-dU) replacing dT.

217 dine-positive (or Ki67(+) ) and 5-ethynyl-2'-deoxyuridine-negative (Ki67(-) ) cells was inversely rel

218 paired posttraumatic neurogenesis (5-bromo-2-deoxyuridine + NeuN-positive cells).

219 peptide and a ureido linkage as well as a 3'-deoxyuridine nucleoside attached to DABA(3) of the pepti

220 Three 5-modified 2'-deoxyuridine nucleosides were synthesized and incorporat

221 n rate was analyzed measuring the 5-bromo-2'-deoxyuridine nucleotide uptake.

222 pe 1 virions and deaminates deoxycytidine to deoxyuridine on nascent minus-strand retroviral cDNA, le

223 anine) were attached to the 5-position of 2'-deoxyuridine or 2'-deoxycytidine through a propyne linke

224 uridine inhibited its isomerization while 2'-deoxyuridine or 4-thiouridine did not.

225 o, unless supplemented with uracil, uridine, deoxyuridine or UMP.

226 idine phosphorylase treated with 5-fluoro-2'-deoxyuridine or uridine, plus sulfate.

227 rmanes gave (Z)-5-(2-germylvinyl)uridine, 2'-deoxyuridine, or ara-uridine as major products.

228 eloped protocols for 2'-N-methyl-2'-amino-2'-deoxyuridine phosphoramidites that are functionalized at

229 C2'-pyrene-functionalized triazole-linked 2'-deoxyuridine phosphoramidites.

230 e aminotransferase; (ii) LipP, a 5'-amino-5'-deoxyuridine phosphorylase; (iii) LipM, a UTP:5-amino-5-

231 significant dose-dependent decrease in bromo-deoxyuridine positive cells was observed.

232 uronal injury and neurogeneration (5-bromo-2-deoxyuridine positive neurons) were quantified on day 7

233 -independent as killing of both 5-ethynyl-2'-deoxyuridine-positive (or Ki67(+) ) and 5-ethynyl-2'-deo

234 roliferation with decreased numbers of bromo-deoxyuridine-positive cells following ketamine exposure

235 In addition, there were fewer 5-bromo-2'-deoxyuridine-positive cells in the LK population in Chd7

236 A significant (P < 0.05) increase in bromo-deoxyuridine-positive epithelia was observed in ventral

237 a combination of immunostaining, 5-bromo-2'-deoxyuridine proliferation assays, and histologic staini

238 ridine ethylene acetal (4b), and 5-formyl-2'-deoxyuridine propylene acetal (5b).

239 T2.1 in the 8-17 DNAzyme was replaced with a deoxyuridine, resulting in minimal change of the DNAzyme

240 We support this model by 5-ethynyl-2'-deoxyuridine retention experiments in shoot and root api

241 ell nuclear antigen, cyclin A, and 5-bromo-2-deoxyuridine reveals that cyclin E promotes progression

242 nt mice treated with exogenous thymidine and deoxyuridine showed reduced survival, body weight, and m

243 Green fluorescent protein and 5-bromo-2'-deoxyuridine staining indicated that persistence of dono

244 According to 5-ethynyl-2'-deoxyuridine staining, few cells (1%) actively cycled un

245 erized by flow cytometry and BrdU (5-bromo-2-deoxyuridine) staining following synchronization of cult

246 ive cells also were costained for 5-bromo-2'-deoxyuridine, suggesting their re-entry into the cell cy

247 Maternal deoxyuridine supplementation prevented NTDs in dams fed

248 lower yields of products such as 5-formyl-2'-deoxyuridine that are ascribable to deprotonation from t

249 Four triphosphates of 2'-deoxyuridine that carried the following bioorthogonally

250 molecules is the biosynthetically unique 3'-deoxyuridine that they share.

251 thylene linkers, or to the 2'-position of 2'-deoxyuridine through a more rigid triazole linker.

252 ion of thymidine or to the 2'-position of 2'-deoxyuridine through triazolemethylene linkers, or to th

253 dine to uracil and ribose 1-phosphate (or 2'-deoxyuridine to 2'-deoxyribose 1-phosphate).

254 ction and used the mitotic marker 5-bromo-2'-deoxyuridine to analyze adult neurogenesis.

255 dditionally, mice were provided 5-ethynyl-2'-deoxyuridine to determine satellite cell proliferation,

256 reversible phosphorolysis of uridine and 2'-deoxyuridine to generate uracil and (2-deoxy)ribose 1-ph

257 ch repair factor MSH2/MSH6, must process the deoxyuridine to initiate class-switch recombination (CSR

258 Using the thymidine analog 5-ethynyl-2'-deoxyuridine to monitor DNA replication of cells of Arab

259 In another design, introducing a deoxyuridine to the 3' position of the deoxycytidine C13

260 identified the folate pathway-related genes, deoxyuridine triphosphatase and dihydrofolate reductase,

261 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) nick end-labeling (TUNE

262 is terminator is based on 5-hydroxymethyl-2'-deoxyuridine triphosphate (HOMedUTP), a hypermodified nu

263 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling assay

264 A deoxyuridine triphosphate derivative carrying a diene at

265 erminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL)-posi

266 erminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling, and caspase

267 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) hist

268 ypothermia also reduced transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)(+) n

269 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL).

270 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling analyses.

271 erminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling and caspase-

272 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assays, resp

273 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, Notch-1, an

274 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling-positive nuc

275 trated that Epstein-Barr virus (EBV)-encoded deoxyuridine triphosphate nucleotidohydrolase (dUTPase)

276 ecent haplotype analyses have suggested that deoxyuridine triphosphate nucleotidohydrolase (dUTPase)

277 Deoxyuridine triphosphate nucleotidohydrolase (dUTPase)

278 the relation between an early viral protein, deoxyuridine triphosphate nucleotidohydrolase (dUTPase),

279 (PAEC) to apoptosis was increased by HERV-K deoxyuridine triphosphate nucleotidohydrolase in an inte

280 Furthermore, 3 weekly injections of HERV-K deoxyuridine triphosphate nucleotidohydrolase induced he

281 HERV-K deoxyuridine triphosphate nucleotidohydrolase induced SA

282 HERV-K envelope and deoxyuridine triphosphate nucleotidohydrolase mRNAs were

283 mmunohistochemistry and Transferase-mediated deoxyuridine triphosphate-biotin nick end labelling (TUN

284 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling (TUNE

285 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling analy

286 labeling using the cyclopropene-modified 2'-deoxyuridine triphosphate.

287 he dephosphorysynthase pathway that includes deoxyuridine triphosphatelation of [(3)H]TMP to [(3)H]th

288 egakaryocytes exhibiting enhanced 5-bromo-2'-deoxyuridine uptake and increased expression of messenge

289 oliferation as indicated by lower 5-bromo-2'-deoxyuridine uptake, increased apoptosis, and reduced ex

290 (a) proliferation, as measured by 5-bromo-2'-deoxyuridine uptake, is higher in the LN than in the pri

291 less cytostatic metabolite 2',2'-difluoro-2'-deoxyuridine was observed, both in cell extracts and spe

292 A 1-h pulse of the nucleotide 5-ethynyl-2'-deoxyuridine was sufficient to label 5% of DCs in both l

293 Tetraphenyl porphyrin substituted deoxyuridine was used as a building block to create disc

294 obtained when 5-fluorouracil or 5-fluoro-2'-deoxyuridine was used instead of CD/5-FC.

295 and supplemented with uridine, thymidine, or deoxyuridine were bred, and litters (n = 10-23 per group

296 ycytidine residues in single-stranded DNA to deoxyuridines, which are then processed by DNA replicati

297 yrimidine nucleosides uridine, thymidine, or deoxyuridine with and without folate deficiency on NTD i

298 D) catalyses deamination of deoxycytidine to deoxyuridine within immunoglobulin loci, triggering path

299 ugar-protected 6-cyanouridine and 6-cyano-2'-deoxyuridine without the protection at the N(3)-imide an

300 e-specific insertion of 5-(3-aminopropyl)-2'-deoxyuridine (Z3dU) and 7-deaza-dG into the Dickerson-Dr